News headlines about OpGen (NASDAQ:OPGN) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OpGen earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 45.8519079525757 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have effected Accern’s scoring:

A number of research firms have recently issued reports on OPGN. Zacks Investment Research cut shares of OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, September 13th. HC Wainwright set a $1.00 target price on shares of OpGen and gave the company a “buy” rating in a research note on Wednesday, August 9th.

OpGen (OPGN) opened at $0.24 on Wednesday. OpGen has a one year low of $0.20 and a one year high of $3.10. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.13 and a current ratio of 1.23.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect OpGen (OPGN) Stock Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Insider Buying and Selling by Quarter for OpGen (NASDAQ:OPGN)

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.